Jangsoon Lee

Jangsoon Lee

UNVERIFIED PROFILE

Are you Jangsoon Lee?   Register this Author

Register author
Jangsoon Lee

Jangsoon Lee

Publications by authors named "Jangsoon Lee"

Are you Jangsoon Lee?   Register this Author

21Publications

449Reads

14Profile Views

Correction to: Anti-tumor and anti-metastasis efficacy of E6201, a MEK1 inhibitor, in preclinical models of triple-negative breast cancer.

Breast Cancer Res Treat 2019 07;176(1):251

Section of Translational Breast Cancer Research, Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, 77030-4009, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10549-019-05218-8DOI Listing
July 2019

Anti-tumor and anti-metastasis efficacy of E6201, a MEK1 inhibitor, in preclinical models of triple-negative breast cancer.

Breast Cancer Res Treat 2019 Jun 2;175(2):339-351. Epub 2019 Mar 2.

Section of Translational Breast Cancer Research, Morgan Welch Inflammatory Breast Cancer Research Program and Clinic, Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10549-019-05166-3DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6534477PMC
June 2019

Corrigendum to "p85 beta-PIX is required for cell motility through phosphorylations of focal adhesion kinase and p38 MAP kinase"[Exp. Cell Res. 307(2) (2005) 315-328].

Exp Cell Res 2019 Jun 13;379(2):245-247. Epub 2019 Apr 13.

Department of Pharmacology, College of Medicine, Konyang University, Nonsan, 320-711, Republic of Korea. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.yexcr.2019.03.030DOI Listing
June 2019

Histone Deacetylase Inhibitor Enhances the Efficacy of MEK Inhibitor through NOXA-Mediated MCL1 Degradation in Triple-Negative and Inflammatory Breast Cancer.

Clin Cancer Res 2017 Aug 2;23(16):4780-4792. Epub 2017 May 2.

Section of Translational Breast Cancer Research, Morgan Welch Inflammatory Breast Cancer Research Program and Clinic, Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-16-2622DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5559319PMC
August 2017

MEK and PI3K catalytic activity as predictor of the response to molecularly targeted agents in triple-negative breast cancer.

Biochem Biophys Res Commun 2017 08 30;489(4):484-489. Epub 2017 May 30.

Graduate School of Life and Environmental Sciences, Osaka Prefecture University, 1-1 Gakuen-cho, Naka-ku, Sakai, Osaka 599-8531, Japan. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bbrc.2017.05.177DOI Listing
August 2017

MEK Inhibitor Selumetinib (AZD6244; ARRY-142886) Prevents Lung Metastasis in a Triple-Negative Breast Cancer Xenograft Model.

Mol Cancer Ther 2015 Dec 17;14(12):2773-81. Epub 2015 Sep 17.

Section of Translational Breast Cancer Research, Houston, Texas. Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1535-7163.MCT-15-0243DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4674314PMC
December 2015

Comprehensive Two- and Three-Dimensional RNAi Screening Identifies PI3K Inhibition as a Complement to MEK Inhibitor AS703026 for Combination Treatment of Triple-Negative Breast Cancer.

J Cancer 2015 28;6(12):1306-19. Epub 2015 Oct 28.

2. Department of Bioinformatics and Computational Biology - Unit 1410, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd., Houston, TX, 77030, USA;

View Article

Download full-text PDF

Source
http://dx.doi.org/10.7150/jca.13266DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4643087PMC
December 2015

Development of PEA-15 using a potent non-viral vector for therapeutic application in breast cancer.

Cancer Lett 2015 Jan 7;356(2 Pt B):374-381. Epub 2014 Oct 7.

Department of Breast Oncology, Sun Yat-Sen University Cancer Center, Guangzhou, People's Republic of China.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.canlet.2014.09.033DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4571276PMC
January 2015

cMET Activation and EGFR-Directed Therapy Resistance in Triple-Negative Breast Cancer.

J Cancer 2014 15;5(9):745-53. Epub 2014 Oct 15.

1. Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA ; 3. Department of Systems Biology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.7150/jca.9696DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4216798PMC
November 2014

A class I histone deacetylase inhibitor, entinostat, enhances lapatinib efficacy in HER2-overexpressing breast cancer cells through FOXO3-mediated Bim1 expression.

Breast Cancer Res Treat 2014 Jul 12;146(2):259-72. Epub 2014 Jun 12.

Section of Translational Breast Cancer Research, Morgan Welch Inflammatory Breast Cancer Research Program and Clinic, Department of Breast Medical Oncology, Unit 1354, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX, 77030, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10549-014-3014-7DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4119423PMC
July 2014

MEK1/2 inhibitor selumetinib (AZD6244) inhibits growth of ovarian clear cell carcinoma in a PEA-15-dependent manner in a mouse xenograft model.

Mol Cancer Ther 2012 Feb 5;11(2):360-9. Epub 2011 Dec 5.

Breast Cancer Translational Research Laboratory, University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1535-7163.MCT-11-0400DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3320047PMC
February 2012

Prevention of bronchial hyperplasia by EGFR pathway inhibitors in an organotypic culture model.

Cancer Prev Res (Phila) 2011 Aug 19;4(8):1306-15. Epub 2011 Apr 19.

Department of Thoracic/Head and Neck Medical Oncology, Unit 432, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd., Houston, TX 77030, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1940-6207.CAPR-10-0364DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3151315PMC
August 2011

Norepinephrine induces VEGF expression and angiogenesis by a hypoxia-inducible factor-1α protein-dependent mechanism.

Int J Cancer 2011 May 13;128(10):2306-16. Epub 2010 Oct 13.

Department of Pharmacology, Myunggok Medical Research Institute, College of Medicine, Konyang University, Daejeon, Republic of Korea.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/ijc.25589DOI Listing
May 2011

Hypoxia enhances LPA-induced HIF-1alpha and VEGF expression: their inhibition by resveratrol.

Cancer Lett 2007 Dec 4;258(1):63-9. Epub 2007 Oct 4.

College of Medicine, Konyang University, Seo-Gu, Daejeon, Republic of Korea.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.canlet.2007.08.011DOI Listing
December 2007

p85 beta-PIX is required for cell motility through phosphorylations of focal adhesion kinase and p38 MAP kinase.

Exp Cell Res 2005 Jul;307(2):315-28

Department of Pharmacology, College of Medicine, Konyang University, Nonsan, 320-711, Republic of Korea.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.yexcr.2005.03.028DOI Listing
July 2005